Diversification of the Earnings Structure and Sustainable Growth Under the Second Medium-Term Management Plan
First written in FY2016. 6 of 8 entries say "Restated". Latest entry: FY2018.
2 other companies' latest entry also says "Other".
- FY2018Plan review: partially achievedAnnual report
「The company reaffirmed a research and development policy focused primarily on the central nervous system, oncology, and cardiovascular and renal areas to meet unmet medical needs.」
The company continues to pursue the policy of making the central nervous system, oncology, and cardiovascular and renal areas its primary focus in research and development in order to address unmet medical needs. - FY2018-Q3RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and Rexulti and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the antineoplastic drug Lonsurf as one of its next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The company continues to pursue sustainable growth targets based on the Second Medium-Term Management Plan. - FY2018-Q2RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and Rexulti and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the antineoplastic drug Lonsurf as one of its next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The company reaffirmed the Second Medium-Term Management Plan, ending in fiscal 2018, and the sustainable growth targets based on that plan. - FY2018-Q1RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and Rexulti and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the antineoplastic drug Lonsurf as one of its next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The company reaffirmed the Second Medium-Term Management Plan, ending in fiscal 2018, and the sustainable growth targets based on that plan. - FY2017RestatedAnnual report
「Under the Second Medium-Term Management Plan, the company offset the impact of the expiration of exclusive sales rights for Abilify through increased revenue from new products, thereby achieving a more diversified earnings structure. In addition, reforms to the earnings power of the nutraceuticals-related business lifted the operating profit margin of that business segment above 10%.」
The company concluded that it achieved diversification of the earnings structure and an operating profit margin of more than 10% in the nutraceuticals-related business under the Second Medium-Term Management Plan, ending in fiscal 2018, while noting that some plan targets, including revenue and operating profit, were not achieved. - FY2017-Q3RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and REXULTI and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the antineoplastic drug Lonsurf as one of its next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The company reaffirmed its sustainable growth targets based on the Second Medium-Term Management Plan. - FY2017-Q2RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and REXULTI and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the antineoplastic drug Lonsurf as one of its next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The company reaffirmed the continuation of the Second Medium-Term Management Plan and its sustainable growth targets based on the plan. The statement does not explicitly refer to diversification of the earnings structure. - FY2016First statedAnnual report
「To realize its corporate philosophy, “Otsuka-people creating new products for better health worldwide” (creating innovative products that contribute to the health of people worldwide), the Otsuka Group formulated its Second Medium-Term Management Plan, ending in fiscal 2018, and is pursuing specific initiatives. Under the Second Medium-Term Management Plan, the Group will establish a diversified earnings structure and achieve sustainable growth through continued investment and structural reform.」
The overall objectives of the Second Medium-Term Management Plan, ending in fiscal 2018, and the themes of earnings-structure diversification, continued investment and structural reform were identified separately for the first time.